The New Reality: Maximizing Value in Rare Disease Launches

Provided By:

Cello Health

September 7, 2017

The rare disease landscape is changing: with assets being granted expedited review, launch is no longer a fixed point in time, and research and development (R&D), medical affairs, and commercial teams need to collaborate early in the process to reach critical consensus on where to focus, when to engage key health care provider (HCP) stakeholders, how to reach patients and caregivers, and what to say about the relative value and impact the asset will have in the market.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK